In the post-Covid world, we have seen the value of ten years of reshaping in clinical trials consolidated in less than a year. Although the life sciences industry is slowly moving towards decentralized clinical trials and wider inclusiveness, Covid-19 has exposed gaps in coverage and efficiency that can no longer be ignored. Looking to the future, industry leaders will focus on three types of clinical trial operating models: modernization and “open”:
- recruitment
- participate
- monitor
For companies in the life sciences industry, adapting to the unprecedented challenge of patient interaction in the pandemic era can only be eclipsed by waiting for the return of the other party. The company is expected to achieve better results, fewer failed trials, better market acceptance, and increased trust among doctors and patients. Patients will get better and more effective equipment and drug therapies to reflect the health needs of different groups of people.
From Lab to Home: How Institutions Optimistically Design Covid Era Experiments
The biggest change that has changed the landscape of clinical trials is the shift from the laboratory to the family. During Covid-19, many hospitals and research institutions switched from face-to-face clinical trials to reporting at home. Unlike trial participants who have traditionally traveled to hospitals, medical offices, or special clinics to participate in trials, trial participants registered in 2020 are increasingly participating in decentralized testing, which makes the experience more accessible.
For decision makers in life sciences and pharmaceutical companies, the obvious question of the integrity of remote and partial telemedicine trials is imminent. First, when a company cannot adapt, it must understand what it has lost. In the first half of 2020, nearly 6,000 medical trials The cessation has nothing to do with the Covid-19 outbreak. Some obstacles to successful trials during pandemic and non-pandemic periods include:
- The inability to recruit participants beyond the “commuting distance” of hospitals or universities leads to admission challenges.
- Unable to be faithful to the established test plan that requires face-to-face contact.
- Based on the safety concerns of registered participants, the intervention and outcome evaluation lack reliability.
- Participants were hesitant to enter the hospital.
- Limited time for potential patients.
A successful, completely remote study assessing whether Compared to placebo, fluvoxamine improved outcomes in 152 outpatients newly diagnosed with Covid-19 Research done in St. Louis in 2020 shows that it is possible to complete the research No contact with any patientFor this study, eligibility was verified via phone and email. Next, the researchers verified each COVID diagnosis using electronic health record reviews. Participants in this unprecedented study conducted self-assessments with the help of virtual and telephone conversations with researchers, using equipment shipped to their homes.
This successful remote test is not unusual.A survey of 245 clinical trial researchers showed that remote interactions 9% in January 2020, 57% in May 2020. Survey participants listed remote activities as basic Tools to facilitate the progress of trials during a pandemic. Tools used to support remote testing include:
- Physical activity monitors, pulse oximeters, and other devices used to measure results.
- Network/video interaction.
- Home visit.
- The fulcrum for outdoor visits to intervene and measure results.
recently Scientific American articlesSeveral well-known researchers shared their optimism that the new opening to remote testing will help advance research. In the first few months of Covid-19, the MD Anderson Cancer Center in Houston transferred its participation in registration and follow-up to telephone and video. The need for secure communications is the catalyst for the institution to modernize patient interaction.
“One of the big things we have been eager to do for years is to establish remote consent.” Jennifer Keating Litton told Scientific American When talking about her experience as president of clinical research during Covid-19. MD Anderson now allows patients to sign all consent forms online. AstraZeneca has similar optimism. As the head of oncology research, José Baselga sees the pandemic as a catalyst for radical changes in cancer research. Researchers believe that remote monitoring is a convenient and safe choice that should have been long since.
“Instead of waiting for them to show up in the emergency room with illness and pain, we can intervene before then,” Baselga shared with Scientific American. Baselga sees significant benefits of relying on remote monitoring. Compared with the habit of performing laboratory work every three weeks, monitoring heart rate, breathing, and other body functions, combined with the patient’s daily self-reports of symptoms and appetite, can create a more accurate assessment.
Take inspiration from big players in the pharmaceutical and health fields
No company is reshaping the landscape of clinical trials like CVS. In 2021, CVS Health launched the CVS Health clinical trial service, whose mission is to make clinical trial research more accessible to all communities in order to improve health outcomes and increase the effectiveness of clinical trials. Although CVS Health is currently focusing on COVID-19 management, the long-term goal of entering clinical trials is to allow more people to participate in the development of all drugs.
According to CVS Health, Less than 4% of the U.S. population participates in clinical researchCVS Health also cited 80% of studies that failed to meet the deadline for participant registration. More than 30% of study participants withdrew before the study was completed. In order to attract and retain more diverse groups of people in future research, CVS Health has taken the initiative to create a more efficient and convenient experience in an all-round way.
The core of the blueprint is more precise patient recruitment. CVS Health is working with various biopharmaceutical and technology companies to use analytics, marketing influence, and community connections to let more people know about opportunities to participate in clinical trials. The second core principle is to use decentralized Phase III and Phase IV trial options to better deliver trials. This shift will allow study participants to interact with clinical researchers either virtual or at CVS locations. Third, CVS Health is moving away from focusing solely on observation in a controlled laboratory environment. The brand plans to use technology to use real-world evidence to test “in the wild” therapies and devices. The world does not have to wait to see if CVS Health’s ambitious plan will work. During the development of the Covid-19 vaccine, CVS Health worked with the pharmaceutical industry to use its enhanced screening protocol and digital communications to attract more than 300,000 volunteers nationwide to meet the inclusion criteria for vaccine trials.
Conclusion: Future clinical trials will be more adaptable and inclusive
For life science companies, there is no such thing as being too adaptable. Although Covid-19 is accelerating agreement adjustments, it is clear that these changes will continue beyond the pandemic. Getting rid of the restrictive norms of recruiting and interacting with patients, researchers are looking for ways to allow more people to participate in trials by simply allowing registration and participation to be free from geographical restrictions and the availability of “working hours”. If this momentum can be maintained, the result will be fewer abandonment of trials, greater trust in the life sciences industry, and upgraded product development.
